Non-alcoholic steatohepatitis: An overview

Journal of the Formosan Medical Association

Volumn 108, Issue 1, 2009, Pages 4-12

  Shifflet, Allison ^a   Wu, George Y ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

Fatty liver; Metabolic syndrome; Steatohepatitis; Steatosis

Indexed keywords

ADIPONECTIN; ALANINE AMINOTRANSFERASE; ALBUMIN; ALPHA TOCOPHEROL; ANGIOTENSIN; ASPARTATE AMINOTRANSFERASE; CLOFIBRATE; CYTOKINE; ENDOTHELIN 1; FATTY ACID; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; IRON; LEPTIN; LIPID; METFORMIN; PIOGLITAZONE; PLACEBO; PRAVASTATIN; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE; RESISTIN; ROSIGLITAZONE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TROGLITAZONE; TUMOR NECROSIS FACTOR; URSODEOXYCHOLIC ACID;

AFRICAN AMERICAN; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BARIATRIC SURGERY; BODY FAT; CAUCASIAN; CHINA; CHINESE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC PROCEDURE; DIET RESTRICTION; DISEASE ACTIVITY; DISEASE ASSOCIATION; ECHOGRAPHY; EXERCISE; FATTY LIVER; GASTRIC BANDING; HISPANIC; HONG KONG; HUMAN; HYPERINSULINEMIA; INSULIN RESISTANCE; KOREA; LIPID PEROXIDATION; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER DYSFUNCTION; LIVER FAILURE; MEDICAL DECISION MAKING; NONALCOHOLIC FATTY LIVER; OBESITY; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PREVALENCE; REVIEW; RISK ASSESSMENT; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; SIDE EFFECT; STOMACH BYPASS; TAIWAN; THROMBOCYTE COUNT; TREATMENT DURATION; TREATMENT OUTCOME; UNITED STATES; WEIGHT REDUCTION;

EID: 60149095703     PISSN: 09296646     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0929-6646(09)60026-7     Document Type: Review

References (75)

1. Clark JM, Diehl AM. Defining nonalcoholic fatty liver disease: implications for epidemiologic studies. Gastroenterology 2003;124:248-50.
2. McCullough AJ. The epidemiology and risk factors of NASH. In: Farrell GC, George J, Hall P, et al, eds. Fatty Liver Disease: NASH and Related Disorders. Oxford: Blackwell, 2005:23-37.
3. Chen CH, Juang MH, Yang J, et al. Prevalence and risk factors of nonalcoholic fatty liver disease in an adult population of Taiwan: metabolic significance of nonalcoholic fatty liver disease in nonbese adults. J Clin Gastroenterol 2006;40:745-52.
4. Yiu DC, Leung NW. Epidemiological study: nonalcoholic fatty liver disease in Hong Kong Chinese. Hepatology 2004;40(Suppl 1):582A.
5. Fan JG, Zhu J, Li XJ, et al. Fatty liver and the metabolic syndrome among Shanghai adults. J Gastroenterol Hepatol 2005;20:1825-32.
6. Park SH, Jeon WK, Kim SH, et al. Prevalence and risk factors of non-alcoholic fatty liver disease among Korean adults. J Gastroenterol Hepatol 2006;21:138-43.
7. Browning JD, Szcezepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004;40: 1387-95.
8. Matteoni CA, Younossi ZM, Gramlich T, et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999;166:1413-9.
9. Bacon BR, Farahvash MJ, Janney CG, et al. Non-alcoholic steatohepatitis: an expanded clinical entity. Gastroenterology 1994;107:1103-9.
10. Powell EE, Cooksley WGE, Hanson RR, et al. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology 1990; 11:74-80.
11. James OFW, Day CP. Non-alcoholic steatohepatitis (NASH): a disease of emerging identity and importance. J Hepatology 1998;29:495-501.
12. Marchesini G, Brizi M, Bianchi G, et al, Non-alcoholic fatty liver disease. A feature of the metabolic syndrome. Diabetes 2001;50:1844-50.
13. Mills SJ, Harrison SA. Comparison of the natural history of alcoholic and nonalcoholic fatty liver disease. Curr Gastroentrol Rev 2005;7:32-6.
14. Day CP, Saksena S. Nonalcoholic steatohepatitis: definitions and pathogenesis. J Gastro Hepatol 2002;17:5377-84.
15. Edmison J, McCullough AJ. Pathogenesis of non-alcoholic steatohepatitis: human data. Clin Liv Dis 2007;11:75-104.
16. Crespo J, Canyon A, Fernanzed-Gil P, et al. Gene expression of tumor necrosis factor alpha and TNF receptors, p55 and p75 in nonalcoholic steatohepatitis patients. Hepatology 2001;24:1158-63.
17. Ueki K, Kondo T, Tseng YH, et al. Central role of suppressors of cytokine signaling proteins in hepatic steatosis, insulin resistance and the metabolic syndrome of the mouse. Proc Natl Acad Sci USA 2004;101:10422-7.
18. Ueki K, Kondo T, Kahn CR. Suppressor of cytokine signaling 1 (SOCS-1) and SOCS-3 cause insulin resistance through inhibition of tyrosine phosphorylation of insulin receptor substrate proteins by discrete mechanisms. Mol Cell Biol 2004;24:5434-46.
19. Samuel VT, Liu ZX, Qu X, et al. Mechanisms of hepatic insulin resistance in non-alcoholic fatty liver disease. J Biol Chem 2004;279:32345-53.
20. Hotamisligil GS, Peraldi A, Budavari A, et al. IRS-1 mediated kinase activity in TNF-alpha and obesity induced insulin resistance. Science 1996;272:665-8.
21. Yamauchi T, Kamon J, Minokoshi Y, et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 2002;8: 1288-95.
22. Spranger J, Kruke A, Mohlig M, et al. Adiponectin and protection against type 2 diabetes mellitus. Lancet 2003;361: 226-8.
23. Hui JM, Hodge A, Farrell GC, et al. Beyond insulin resistance in NASH: TNF-alpha or adiponectin? Hepatology 2004;40:46-54.
24. Soodini GR, Hamdy O. Adiponectin and leptin in relation to insulin sensitivity. Metab Synd Rel Dis 2004;2:114-23.
25. Kaser S, Moschen A, Cayon A, et al. Adiponectin and its receptors in nonalcoholic steatohepatitis. Gut 2005;54: 117-21.
26. Xu A, Want Y, Keshaw H, et al. The fat derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest 2003;112:91-100.
27. Yoshi H, Kuriyama S, Yoshii J, et al. Angiotensin-II type 1 receptor interaction is a major regulator for liver fibrosis development in rats. Hepatology 2001;34:745-50.
28. Bataller R, Sancho-Bru P, Gines P, et al. Liver fibrogenesis: a new role for the renin-angiotensin system. Antioxid Redox Signal 2005;7:1346-55.
29. Wei YH, Jun L, Quiang CJ. Effect of losartan, an angiotensin II antagonist, on hepatic fibrosis induced by CC14 in rats. Dig Dis Sci 2004;49:1589-94.
30. Yokohama S, Yoneda M, Haneda M, et al. Therapeutic efficacy of an angiotensinogen II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology 2004;40: 1222-5.
31. Stewart S, Jones D, Day CP. Alcoholic liver disease: new insights into mechanisms and preventative strategies. Trends Mol Med 2001;7:408-13.
32. Li XL, Man K, Ng KT, et al. Insulin in UW solution exacerbates hepatic ischemia/reperfusion injury by energy depletion through the IRS-2/ SREBP-1c pathway. Liver Transpl 2004;10:1172-82.
33. Paradis V, Perle G, Bonvoust F, et al. High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis. Hepatology 2001; 74:738-44.
34. Rauen U, Petrat F, Sustmann R, et al. Iron induced mitochondrial permeability transition in cultured hepatocytes. J Hepatology 2004;40:607-15.
35. Fargion S, Mattioli M, Fracanzani AL, et al. Hyperferritinemia, iron overload, and multiple metabolic alterations identify patients at risk for nonalcoholic steatohepatitis. Am J Gastroenterol 2001;96:2448-55.
36. Fernandez Real JM, Casamitjana-Abella R, Ricart-Engel W, et al. Serum ferritin as a component of the insulin resistance syndrome. Diabetes Care 1998;21:62-8.
37. Riquelme A, Soza A, Nazal L, et al. Histological resolution of steatohepatitis after iron depletion. Dig Dis Sci 2004;49: 1012-5.
38. Marchesini G, Brizi M, Bianchi G, et al. Nonalcoholic fatty liver disease. A feature of the metabolic syndrome. Diabetes 2001;50:1844-50.
39. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histologic scoring system for nonalcoholic fatty liver disease. Hepatology 2005;41:1313-21.
40. Merriman RB, Ferrell LD, Patti MG, et al. Correlation of paired liver biopsies in morbidly obese patients with suspected nonalcoholic fatty liver disease. Hepatology 2006; 44:874-80.
41. Arun J, Jhala, N, Lazenby AJ, et al. Influence of liver biopsy heterogeneity and diagnosis of nonalcoholic steatohepatitis in subjects undergoing gastric bypass. Obes Surg 2007;17: 155-61.
42. Ratziu V, Charlotte F, Heurtier A, et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 2005;128:1898-906.
43. Adams LA, Talwalker JA. Diagnostic evaluation of nonalcoholic fatty liver disease. J Clin Gastroenterol 2006;40:S34-8.
44. Kawata R, Sakata K, Kunieda T, et al. Quantitative evaluation of fatty liver by computed tomography in rabbits. AJR Am J Roentgenol 1984:142:741-6.
45. Oliva MR, Mortele KJ, Segatto E, et al. Computed tomography features of non-alcoholic steatohepatitis with histopathologic correlation. J Comput Assist Tomagr 2006; 30:37-43.
46. Saadeh S, Younossi ZM, Remer EM, et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002;123:745-50.
47. Chave G, Milot L, Pilleul F. Out of phase magnetic resonance imaging and liver applications. J Radiol 2005;86:993-7.
48. Suzuki A, Angulo P, Lymph J, et al. Hyaluronic acid, an accurate serum marker for severe hepatic fibrosis in patients with non-alcoholic fatty liver disease. Liver Int 2005;25:779-86.
49. Degertegin B, Ozenirler S, Elbeg S, et al. Serum endothelin-1 level in steatosis and NASH, and its relation with severity of liver fibrosis. Dig Dis Sci 2007;52:2622-8.
50. Angulo P, Hui JM, Marchesini G, et al. The NAFLD fibrosis score: a noninvasive system that accurately identifies liver fibrosis in patients with NAFLD. Hepatology 2007;45: 846-54.
51. Guha IN, Parkes J, Roderick P, et al. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: validating the European liver fibrosis panel and exploring simple markers. Hepatology 2008;47:455-60.
52. Palmer M, Schaffner F. Effect of weight reduction on hepatic abnormalities in overweight patients. Gastroenterology 1990;99:1408-13.
53. Ueno T, Sugawara H, Sujaku K, et al. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J Hepatol 1997;27:103-7.
54. Knobler H, Schattner A, Zhornicki T, et al. Fatty liver - an additional and treatable feature of the insulin resistance syndrome. QJM 1999;92:73-9.
55. Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, et al. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology 2003;38:1008-17.
56. Lutchman G, Promrat K, Kleiner DE, et al. Durability of histological and biochemical improvement after stopping pioglitazone therapy for nonalcoholic steatohepatitis. Is long-term therapy needed? Gastroenterology 2005;128 (4 Suppl 2):A695.
57. Belfort R, Harrison S, Brown K, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steato-hepatitis. N Engl J Med 2006;355:2297-307.
58. Gitlin N, Julie NL, Spurr CL, et al. Two cases of severe clinical and histologic hepatotoxicity associated with troglitazone. Ann Intern Med 1998;129:36-8.
59. Watkins PB, Whitcomb RW. Hepatic dysfunction associated with troglitazone. N Engl J Med 1998;338:916-7.
60. Uygun A, Kadayifci A, Isik AT, et al. Metformin in the treatment of patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2004;19:537-44.
61. Bugianesi E, Gentilcore E, Manini R, et al. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am J Gastroenterol 2005;100:1082-90.
62. Hasegawa T, Yoneda M, Nakamura K, et al. Plasma transforming growth factor-beta 1 level and efficacy of alpha-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study. Aliment Pharmacol Ther 2001;15:1667-72.
63. Kugelmas M, Hill DB, Vivian B, et al. Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E. Hepatology 2003;38:413-9.
64. Lindor KD, Kowdley KV, Heathcote EJ, et al. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology 2004;39:770-8.
65. Basaranoglu M, Acbay O, Sonsuz A. A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis. J Hepatol 1999;31:384.
66. Lindor KD, Kowdley KF, Heathcote EJ, et al. Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study. Hepatology 1996;23:1464-7.
67. Kiyici M, Gulten M, Gurel S, et al. Ursodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitis. Can J Gastroenterol 2003;17:713-8.
68. Rallidis LS, Drakoulis CK, Parasi AS. Pravastatin in patients with nonalcoholic steatohepatitis: results of a pilot study. Atherosclerosis 2004;174:193-6.
69. Chapman A, Kiroff G, Game P, et al. Laparoscopic adjustable gastric banding in the treatment of obesity: a systematic review. Surgery 2004;135:326-51.
70. Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery: a systematic review and metanalysis. JAMA 2004;292: 1724-37.
71. Maggard MA, Shugarman LR, Suttorp M, et al. Meta-analysis: surgical treatment of obesity. Ann Intern Med 2005;142:547-59.
72. Mattar SG, Velcum LM, Rabinovitz M, et al. Surgically-induced weight loss significantly improves nonalcoholic fatty liver disease and the metabolic syndrome. Ann Surg 2005;242:610-7.
73. Clark JM, Alkhuraishi AR, Solga SF, et al. Roux-en-Y gastric bypass improves liver histology in patients with non-alcoholic fatty liver disease. Obes Res 2005;13:1180-6.
74. de Almeida SR, Rocha PR, Sanches MD, et al. Roux-en-Y gastric bypass improves the nonalcoholic steatohepatitis (NASH) of morbid obesity. Obes Surg 2006;16:270-8.
75. Neuschwander-Tetri BA, Cladwell SH. Nonalcoholic steatohepatitis: summary of an AASLD single topic conference. Hepatology 2003;37:1202-19.